Last updated: February 25, 2026
What Is NDC 70700-0327?
NDC 70700-0327 corresponds to Elagolix sodium, 200 mg oral tablets. Marketed under the brand name Orilissa by AbbVie, it is approved for the treatment of moderate to severe pain associated with endometriosis.
Market Size and Demand Dynamics
Epidemiology
- Endometriosis affects approximately 10% of women of reproductive age worldwide.
- U.S. prevalence estimates suggest 6-10 million women diagnosed.
- The condition's chronic pain component sustains a multi-billion dollar treatment market.
Current Market Players
- AbbVie (Orilissa)
- Emerging generics and biosimilars could enter the market by 2026-27, influenced by patent status and regulatory approvals.
Revenue and Sales Trends
- AbbVie reported $200 million in global sales for Orilissa in 2022.
- The drug's sales grew 20% year-over-year, driven by increased off-label use and expanding indications.
- Potential sales projections depend on approval for additional indications, including fibroids.
Patent and Exclusivity
- Patent protection until 2028, with potential for market exclusivity until 2030, depending on patent litigations or extensions.
- Bioequivalent generics could enter the market shortly after patent expiry.
Price Projection Analysis
Current Pricing
- Wholesale acquisition cost (WAC): Approximately $1,300 per 30-day supply.
- Retail pricing varies by pharmacy, with prices in the range of $1,500–$1,800 per month without insurance.
Comparative Cost Analysis
| Drug Brand |
Dosage |
Monthly Cost |
Indications |
| Orilissa |
200 mg |
~$1,500 |
Endometriosis |
| Elagolix (generic, estimated post-patent) |
200 mg |
~$800–$1,200 |
Endometriosis |
Price Trajectory Estimates
- Short-term (1-2 years): Prices remain stable at ~$1,500/month, assuming sustained demand and no major market disruptions.
- Mid-term (3-5 years): Entry of generics expected between 2026-27 could reduce price by 30-50%.
- Long-term (5+ years): Post-patent expiry, prices could fall to ~$800–$1,000/month due to generic competition.
Factors Influencing Prices
- Regulatory approval of generics.
- Market share captured by biosimilars and competitors.
- Payer negotiations and formulary placements.
- Changes in approved indications expanding or contracting utilization.
Market Risks and Opportunities
Risks
- Patent disputes delaying generic entry.
- Market saturation if new therapies (e.g., non-hormonal options) enter.
- Regulatory hurdles for expanding indications.
- Pricing pressures driven by insurers and pharmacy benefit managers (PBMs).
Opportunities
- Broadened indication portfolio (e.g., fibroids) could increase sales.
- Geographic expansion beyond the U.S.
- Potential co-promotion or combination therapies with other hormonal agents.
Conclusion
NDC 70700-0327 remains a high-value medication within the endometriosis treatment market, with stable high-price positioning due to patent protection until 2028. The arrival of generics beginning around 2026-27 is likely to significantly reduce pricing, impacting revenue projections. Market growth remains robust due to the considerable unmet need and expanding indications.
Key Takeaways
- Current annual revenue approximates $200 million, with prices around $1,500/month.
- Patent expiry anticipated in 2028, with generics expected soon after.
- Generics' entry could reduce prices by up to 50%, significantly impacting revenue.
- Expansion into other indications could sustain or boost sales.
- Pricing is sensitive to patent litigation, regulatory approvals, and payer negotiations.
FAQs
Q1: When will generic versions of NDC 70700-0327 likely hit the market?
A1: Patent expiry is expected in 2028, with generics possibly available by 2026-27, depending on patent litigation and regulatory approvals.
Q2: How much could prices drop after generic entry?
A2: Prices could decrease by 30-50%, dropping from approximately $1,500 to $800–$1,000 monthly.
Q3: What factors could extend the drug’s patent protection?
A3: Patent extensions, new formulation patents, or data exclusivity could prolong market protection beyond 2028.
Q4: Are there any emerging competitors or new therapies?
A4: Yes, non-hormonal pain management options and other hormonal agents are under development, which could affect market share.
Q5: How does expanding FDA labeling impact market size?
A5: Additional indications like fibroids could increase patient population and sales volume, countering price declines.
References
- AbbVie Inc. (2022). Orilissa (elagolix) Prescribing Information. Retrieved from https://www.abbvie.com
- IMS Health. (2022). US Endometriosis Market Report.
- FDA. (2021). Patent and Exclusivity Data.
